Statements (26)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:CEO |
gptkb:Scott_Liu
|
gptkbp:collaboratesWith |
gptkb:AbbVie
gptkb:Jacobson_Pharma |
gptkbp:country |
gptkb:China
|
gptkbp:focus |
biosimilars
innovative biologics |
gptkbp:founded |
2010
|
gptkbp:headquarters_location |
gptkb:Shanghai
|
https://www.w3.org/2000/01/rdf-schema#label |
Shanghai Henlius Biotech
|
gptkbp:industry |
biopharmaceuticals
|
gptkbp:market |
global
|
gptkbp:numberOfEmployees |
over 1,000
|
gptkbp:parentCompany |
gptkb:Fosun_Pharma
|
gptkbp:product |
gptkb:HLX01_(rituximab_biosimilar)
gptkb:HLX02_(trastuzumab_biosimilar) gptkb:HLX03_(adalimumab_biosimilar) gptkb:HLX04_(bevacizumab_biosimilar) |
gptkbp:researchArea |
oncology
autoimmune diseases |
gptkbp:stockExchange |
gptkb:Hong_Kong_Stock_Exchange
2019 |
gptkbp:stockSymbol |
gptkb:2696.HK
|
gptkbp:website |
https://www.henlius.com
|
gptkbp:bfsParent |
gptkb:Zhangjiang
|
gptkbp:bfsLayer |
6
|